相似文献
1
Considerations on Multimorbidity and Frailty in Inflammatory Bowel Diseases.
J Crohns Colitis. 2024 Oct 30;18(Supplement_2):ii46-ii54. doi: 10.1093/ecco-jcc/jjae067.
2
Frailty: An Underappreciated Risk Factor for IBD Complications.
Curr Gastroenterol Rep. 2024 Dec;26(12):315-322. doi: 10.1007/s11894-024-00945-5. Epub 2024 Sep 5.
3
Multimorbidity among inflammatory bowel disease patients in a tertiary care center: a retrospective study.
BMC Gastroenterol. 2022 Nov 26;22(1):487. doi: 10.1186/s12876-022-02578-2.
4
Challenges in the management of older patients with inflammatory rheumatic diseases.
Nat Rev Rheumatol. 2022 Jun;18(6):326-334. doi: 10.1038/s41584-022-00768-6. Epub 2022 Mar 21.
5
Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study.
Clin Gastroenterol Hepatol. 2022 Oct;20(10):2358-2365.e11. doi: 10.1016/j.cgh.2022.01.001. Epub 2022 Jan 6.
6
An overview of multimorbidity and polypharmacy in older people living with HIV.
Geriatr Gerontol Int. 2024 Mar;24 Suppl 1:49-59. doi: 10.1111/ggi.14717. Epub 2023 Nov 8.
7
Frailty in inflammatory bowel disease: analysis of the National Inpatient Sample 2015-2019.
Colorectal Dis. 2024 May;26(5):958-967. doi: 10.1111/codi.16967. Epub 2024 Apr 4.
8
Prevalence of frailty among patients with inflammatory bowel disease and its association with clinical outcomes: a systematic review and meta-analysis.
BMC Gastroenterol. 2022 Dec 22;22(1):534. doi: 10.1186/s12876-022-02620-3.
9
Aging and IBD: A New Challenge for Clinicians and Researchers.
Inflamm Bowel Dis. 2022 Jan 5;28(1):126-132. doi: 10.1093/ibd/izab039.
10
New horizons in multimorbidity in older adults.
Age Ageing. 2017 Nov 1;46(6):882-888. doi: 10.1093/ageing/afx150.
引用本文的文献
1
IBD Across the Ages－A Journey Together.
J Crohns Colitis. 2024 Oct 30;18(Supplement_2):ii1-ii2. doi: 10.1093/ecco-jcc/jjae118.
本文引用的文献
1
Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study.
Saudi Pharm J. 2023 Sep;31(9):101736. doi: 10.1016/j.jsps.2023.101736. Epub 2023 Aug 5.
2
Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases.
J Clin Med. 2023 Apr 3;12(7):2658. doi: 10.3390/jcm12072658.
3
Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study.
Inflamm Bowel Dis. 2023 Oct 3;29(10):1536-1545. doi: 10.1093/ibd/izad020.
4
Comparative effectiveness of non-pharmacological interventions for frailty: a systematic review and network meta-analysis.
Age Ageing. 2023 Feb 1;52(2). doi: 10.1093/ageing/afad004.
5
Conventional Frailty Index Does Not Predict Risk of Postoperative Complications in Patients With IBD: A Multicenter Cohort Study.
Dis Colon Rectum. 2023 Aug 1;66(8):1085-1094. doi: 10.1097/DCR.0000000000002524. Epub 2022 Dec 15.
6
Prevalence of frailty among patients with inflammatory bowel disease and its association with clinical outcomes: a systematic review and meta-analysis.
BMC Gastroenterol. 2022 Dec 22;22(1):534. doi: 10.1186/s12876-022-02620-3.
7
Frail Phenotype in Patients With Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2023 Oct 3;29(10):1555-1562. doi: 10.1093/ibd/izac242.
8
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program.
Inflamm Bowel Dis. 2023 Jan 5;29(1):27-41. doi: 10.1093/ibd/izac084.
9
Is it time to include older adults in inflammatory bowel disease trials? A call for action.
Lancet Healthy Longev. 2022 May;3(5):e356-e366. doi: 10.1016/S2666-7568(22)00060-5. Epub 2022 May 4.
10
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
J Crohns Colitis. 2023 Jan 27;17(1):83-91. doi: 10.1093/ecco-jcc/jjac108.
Zotero 插件